• 1. Gd-complexes of DTPA-bis(amide) conjugates of tranexamic acid and its esters with high relaxivity and stability for magnetic resonance imaging
  Sujit Dutta,Ji-Ae Park,Jae-Chang Jung,Yongmin Chang,Tae-Jeong Kim Gd-complexes of DTPA-bis(amide) conjugates of tranexamic acid and its esters with high relaxivity and stability for magnetic resonance imaging. Sujit Dutta Ji-Ae Park Jae-Chang Jung Yongmin Chang Tae-Jeong Kim Dalton Trans. 2008 2199
• 2. A lab on a chip device for the determination of tranexamic acid using a peroxyoxalate chemiluminescence system
  Hiader A. J. Al Lawati,Mira M. Al-Nadabi,Gouri B. Varma,Fakhr Eldin O. Suliman Anal. Methods 2013 5 6205
• 3. N-Phthaloyltranexamic acid ammonium salt derivatives as photocaged superbase for redox free radical photopolymerization
  Minghui He,Guangxue Chen,Xun Huang,Ruixin Xu,Zhaohua Zeng,Jianwen Yang Polym. Chem. 2014 5 2951
• 4. Solid phase microextraction coupled to mass spectrometry via a microfluidic open interface for rapid therapeutic drug monitoring
  Nikita T. Looby,Marcos Tascon,Vinicius R. Acquaro,Nathaly Reyes-Garcés,Tijana Vasiljevic,German Augusto Gomez-Rios,Marcin W?sowicz,Janusz Pawliszyn Analyst 2019 144 3721
• 5. Thioxanthone dicarboxamide derivatives as one-component photoinitiators for near-UV and visible LED (365–405 nm) induced photopolymerizations
  Guangxue Chen,Xiaoyuan Guan,Ruixin Xu,Junfei Tian,Fachuang Lu,Minghui He,Jianwen Yang RSC Adv. 2016 6 77093

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Tranexamic Acid Chemical Properties and Pharmacokinetics (CAS 1197-18-8)

Tranexamic acid (TXA), with the CAS number 1197-18-8, is a synthetic derivative of the amino acid lysine, widely recognized for its antifibrinolytic properties. Its molecular formula is C₈H₁₅NO₂, and it functions by competitively inhibiting the activation of plasminogen to plasmin, thereby reducing excessive bleeding. The compound exhibits high water solubility and stability, making it suitable for oral, intravenous, and topical formulations. Recent pharmacokinetic studies highlight its rapid absorption (peak plasma concentration within 3 hours) and renal excretion, with a half-life of approximately 2 hours. Researchers emphasize its low toxicity profile, though dosage adjustments are recommended for patients with renal impairment. The demand for TXA has surged due to its applications in trauma, surgery, and dermatology, aligning with the growing interest in evidence-based hemostatic therapies.

Tranexamic Acid in Clinical Applications (CAS 1197-18-8)

Clinical trials have cemented Tranexamic acid (1197-18-8) as a cornerstone in managing hemorrhage across multiple disciplines. In trauma care, the CRASH-2 trial demonstrated a 15% reduction in mortality when administered early. Obstetrics also benefits from TXA, with the WOMAN trial showing a 31% decrease in death from postpartum hemorrhage. Dermatologically, its melanin-inhibiting effects have made it a popular off-label treatment for hyperpigmentation, particularly in melasma. A 2023 meta-analysis revealed that topical TXA (5% concentration) outperformed hydroquinone in safety and efficacy for facial pigmentation. However, debates persist regarding optimal dosing in elective surgeries, with studies advocating for weight-adjusted protocols to minimize thromboembolic risks. These findings address patient concerns about both efficacy and long-term safety.

Tranexamic Acid Mechanism of Action and Research Advances (CAS 1197-18-8)

The molecular mechanism of 1197-18-8 (Tranexamic acid) involves binding to the lysine sites on plasminogen, blocking its interaction with fibrin. This action preserves clot stability while modulating inflammatory pathways—a discovery that expanded its use in conditions like angioedema. Cutting-edge research explores TXA's neuroprotective potential in traumatic brain injury (TBI), where it may mitigate secondary injury by reducing metalloproteinase-9 activity. A 2024 Nature Communications study identified TXA's role in downregulating PAR-1 receptors, suggesting applications in atherosclerosis. Such breakthroughs respond to the scientific community's demand for drug repurposing strategies, particularly for multifunctional agents like TXA that combine affordability with broad therapeutic windows.

Tranexamic Acid Safety Profile and Global Market Trends (CAS 1197-18-8)

Despite its widespread use, Tranexamic acid (1197-18-8) requires careful risk-benefit analysis in specific populations. The WHO Essential Medicines List inclusion underscores its global importance, with annual prescriptions exceeding 80 million doses. Post-marketing surveillance data indicate a 0.7% incidence of gastrointestinal side effects, while thromboembolic events remain rare (0.2%). The cosmetic industry's adoption of TXA for hyperpigmentation has driven a 12% CAGR in dermatological formulations since 2020. Patent expirations have also spurred generic production, with cost reductions up to 70% in emerging markets. These trends reflect patient priorities for accessible, multipurpose medications with robust safety data, positioning TXA as a model for translational drug development.

• 140218-27-5(Cyclohexanecarboxylic acid, 4-(aminomethyl)-, monopotassium salt,trans-)
• 38876-40-3(Cyclohexanecarboxylic acid, 4-(aminomethyl)-3-methyl-)
• 38876-38-9(4-(aminomethyl)-1-methylcyclohexane-1-carboxylic acid)
• 52794-31-7(52794-31-7)
• 1197-17-7(cis-4-(aminomethyl)cyclohexane-1-carboxylic acid)
• 62618-04-6(Cyclohexanecarboxylic acid, 4-(aminomethyl)-1-methyl-, cis-)
• 61308-28-9(Cyclohexanecarboxylic acid, 4-(aminomethyl)-, monosodium salt, cis- (9CI))
• 24306-54-5(4-(aminomethyl)bicyclo2.2.2octane-1-carboxylic acid)
• 701-54-2(4-(Aminomethyl)cyclohexanecarboxylic Acid)
• 62618-03-5(Cyclohexanecarboxylic acid, 4-(aminomethyl)-1-methyl-, trans-)